Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis
- 2 August 2006
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 7 (9), 741-746
- https://doi.org/10.1016/s1470-2045(06)70800-2
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized TrialsJournal of Clinical Oncology, 2005
- Objective Response Rate As a Surrogate End Point: A CommentaryJournal of Clinical Oncology, 2005
- Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer PatientsJournal of Clinical Oncology, 2005
- Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon CancerNew England Journal of Medicine, 2004
- Policy developments in regulatory approvalStatistics in Medicine, 2002
- Individual patient‐ versus group‐level data meta‐regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly headStatistics in Medicine, 2002
- Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysisThe Lancet, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Empirical Evidence of BiasJAMA, 1995
- Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteriaInvestigational New Drugs, 1992